NASDAQ: VRCAVerrica Pharmaceuticals Inc Stock
$6.84+0.63 (+10.14%)
Updated Jun 26, 2026
VRCA Price
$6.84
Fair Value Price
N/A
Market Cap
$117.50M
52 Week Low
$3.28
52 Week High
$9.82
P/E
-6.16x
P/B
7.32x
P/S
3.03x
PEG
N/A
Dividend Yield
N/A
Revenue
$37.16M
Earnings
-$17.83M
Gross Margin
89.5%
Operating Margin
-32.63%
Profit Margin
-48%
Debt to Equity
1.42
Operating Cash Flow
-$14M
Beta
1.05
Next Earnings
Aug 11, 2026
Ex-Dividend
N/A
Next Dividend
N/A
VRCA Overview
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine VRCA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important VRCA news, forecast changes, insider trades & much more!
VRCA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how VRCA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VRCA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
VRCA is poor value based on its book value relative to its share price (7.32x), compared to the US Biotechnology industry average (5.36x)
P/B vs Industry Valuation
VRCA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more VRCA due diligence checks available for Premium users.
Valuation
VRCA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.16x
Industry
16.11x
Market
12.38x
VRCA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
7.32x
Industry
5.36x
VRCA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VRCA's financial health
Profit margin
Revenue
$5.0M
Net Income
-$9.7M
Profit Margin
-192.8%
VRCA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
VRCA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$38.8M
Liabilities
$22.7M
Debt to equity
1.42
VRCA's short-term assets ($34.13M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VRCA's short-term assets ($34.13M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VRCA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
VRCA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.2M
Investing
$0.0
Financing
-$120.0k
VRCA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VRCA vs Biotech Stocks
Verrica Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.